Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Capital Expenditures (2019 - 2025)

Enliven Therapeutics has reported Capital Expenditures over the past 7 years, most recently at $158000.0 for Q3 2025.

  • Quarterly results put Capital Expenditures at $158000.0 for Q3 2025, up 618.18% from a year ago — trailing twelve months through Mar 2026 was $138000.0 (up 213.64% YoY), and the annual figure for FY2025 was $158000.0, up 259.09%.
  • Capital Expenditures reached $158000.0 in Q3 2025 per ELVN's latest filing, up from -$20000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $303000.0 in Q2 2022 and bottomed at -$31000.0 in Q2 2023.
  • Median Capital Expenditures over the past 5 years was $20000.0 (2024), compared with a mean of $65000.0.
  • The largest annual shift saw Capital Expenditures skyrocketed 1516.67% in 2022 before it tumbled 1100.0% in 2025.
  • Over 5 years, Capital Expenditures stood at $12000.0 in 2021, then surged by 741.67% to $101000.0 in 2022, then crashed by 86.14% to $14000.0 in 2023, then surged by 57.14% to $22000.0 in 2024, then soared by 618.18% to $158000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ELVN at $158000.0 in Q3 2025, -$20000.0 in Q2 2025, and $20000.0 in Q1 2025.